Renewed worries over H. Lundbeck AS's pipeline and prospects resurfaced amid news the Danish CNS specialist's antipsycotic drug Rexulti (brexpiprazole) did not meet the primary endpoint in treating bipolar I manic episodes in two global Phase III trials.
Analysts said the drug's failure in both advanced studies was unexpected and a negative blow to how investors view the...








